NO324117B1 - Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. - Google Patents

Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. Download PDF

Info

Publication number: NO324117B1
Authority: NO; Norway
Prior art keywords: igf; igfbp; complex; insulin; type
Prior art date: 1999-06-04

Application number

NO20015932A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015932L (no

NO20015932D0 (no

Inventor

Andreas Sommer

Original Assignee

Celtrix Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2001-12-04

Publication date

2007-08-27

2001-12-04 Application filed by Celtrix Pharma filed Critical Celtrix Pharma

2001-12-04 Publication of NO20015932D0 publication Critical patent/NO20015932D0/no

2002-01-31 Publication of NO20015932L publication Critical patent/NO20015932L/no

2007-08-27 Publication of NO324117B1 publication Critical patent/NO324117B1/no

Links

102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 title claims abstract description 86
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 title claims abstract description 84
206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 44
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims description 108
102000004218 Insulin-Like Growth Factor I Human genes 0.000 title claims description 92
239000003814 drug Substances 0.000 title claims description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 31
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 19
208000024891 symptom Diseases 0.000 claims abstract description 16
206010022491 Insulin resistant diabetes Diseases 0.000 claims abstract description 5
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 52
102000004877 Insulin Human genes 0.000 claims description 26
108090001061 Insulin Proteins 0.000 claims description 26
229940125396 insulin Drugs 0.000 claims description 26
206010022489 Insulin Resistance Diseases 0.000 claims description 14
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 7
101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 4
102000044162 human IGF1 Human genes 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000011282 treatment Methods 0.000 abstract description 25
238000000034 method Methods 0.000 abstract description 6
230000006641 stabilisation Effects 0.000 abstract description 3
238000011105 stabilization Methods 0.000 abstract description 3
102000013275 Somatomedins Human genes 0.000 description 16
230000000694 effects Effects 0.000 description 13
230000009467 reduction Effects 0.000 description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
239000008103 glucose Substances 0.000 description 9
230000002218 hypoglycaemic effect Effects 0.000 description 9
208000013016 Hypoglycemia Diseases 0.000 description 8
230000002641 glycemic effect Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
230000002354 daily effect Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
102000028416 insulin-like growth factor binding Human genes 0.000 description 7
108091022911 insulin-like growth factor binding Proteins 0.000 description 7
238000007920 subcutaneous administration Methods 0.000 description 7
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 6
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
108010005094 Advanced Glycation End Products Proteins 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 4
206010023379 Ketoacidosis Diseases 0.000 description 4
208000007976 Ketosis Diseases 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
206010033433 Pain in jaw Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
201000001421 hyperglycemia Diseases 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102200099125 rs137853176 Human genes 0.000 description 4
102200124816 rs267607412 Human genes 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000002792 vascular Effects 0.000 description 4
206010052097 Dawn phenomenon Diseases 0.000 description 3
102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
208000029663 Hypophosphatemia Diseases 0.000 description 3
108010077850 Nuclear Localization Signals Proteins 0.000 description 3
102100038803 Somatotropin Human genes 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000007423 decrease Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000002608 insulinlike Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
241000271566 Aves Species 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000002249 Diabetes Complications Diseases 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
230000037213 diet Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
102000057148 human IGFBP3 Human genes 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
102000018386 EGF Family of Proteins Human genes 0.000 description 1
108010066486 EGF Family of Proteins Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Chemical group 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
208000002787 Pregnancy Complications Diseases 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003526 lymphopoietic effect Effects 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
208000012113 pregnancy disease Diseases 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

NO20015932A 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. NO324117B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/326,189 US6040292A (en)	1999-06-04	1999-06-04	Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (fr)	1999-06-04	2000-05-23	Methodes de traitement du diabete

Publications (3)

Publication Number	Publication Date
NO20015932D0 NO20015932D0 (no)	2001-12-04
NO20015932L NO20015932L (no)	2002-01-31
NO324117B1 true NO324117B1 (no)	2007-08-27

Family

ID=23271175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015932A NO324117B1 (no)	1999-06-04	2001-12-04	Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes.

Country Status (15)

Country	Link
US (1)	US6040292A (fr)
EP (1)	EP1183042B1 (fr)
JP (1)	JP2003501397A (fr)
KR (1)	KR100694737B1 (fr)
CN (1)	CN1235637C (fr)
AT (1)	ATE271880T1 (fr)
AU (1)	AU780400B2 (fr)
CA (1)	CA2373281C (fr)
DE (1)	DE60012517T2 (fr)
ES (1)	ES2222208T3 (fr)
IL (1)	IL146868A0 (fr)
MX (1)	MXPA01013384A (fr)
NO (1)	NO324117B1 (fr)
WO (1)	WO2000074710A2 (fr)
ZA (1)	ZA200110408B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) *	2000-07-03	2018-05-31	Bristol-Myers Squibb Company	USE OF HEATED CTLA4 MUTANT MOLECULES
US20030035788A1 (en) *	2000-09-19	2003-02-20	Desmond Mascarenhas	Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20080200453A1 (en)	2002-07-29	2008-08-21	Cincotta Anthony H	Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) *	2002-07-29	2004-11-04	Cincotta Anthony H.	Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) *	2002-07-29	2004-04-22	Cincotta Anthony H.	Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US9655865B2 (en)	2002-07-29	2017-05-23	Veroscience, Llc	Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) *	2002-08-09	2004-04-29	Anthony Cincotta	Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137993B2 (en) *	2004-03-25	2012-03-20	Veroscience Llc	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) *	2004-03-25	2005-09-29	Cincotta Anthony H	Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) *	2004-03-25	2012-03-20	Veroscience Llc	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
JP5743373B2 (ja) *	2004-12-30	2015-07-01	ヒルズ・ペット・ニュートリシャン・インコーポレーテッド	ネコ食餌用の組成物
US8518877B2 (en) *	2007-04-18	2013-08-27	Premacure Ab	Method and product for treatment and/or prevention of complications of prematurity
WO2010096125A1 (fr) *	2008-10-29	2010-08-26	The Rockefeller University	Procédés et kits pour traiter une maladie par administration de protéine 2 de liaison de facteur de croissance insulinomimétique
SG174891A1 (en)	2009-04-01	2011-11-28	Genentech Inc	Treatment of insulin-resistant disorders
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2605771B1 (fr)	2010-08-16	2018-04-04	Allergan, Inc.	Procédé d'activation de lymphocytes t régulateurs avec des agonistes du récepteur adrénergique alpha-2b

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5200509A (en) *	1987-04-06	1993-04-06	Celtrix Pharmaceuticals, Inc.	Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) *	1988-02-05	1991-01-29	Ciba-Geigy Corporation	Method for preventing secondary effects
GB8920381D0 (en) *	1989-09-08	1989-10-25	Greater Glasgow Health Board	Treatment of insulin-resistant diabetes
SE9201573D0 (sv) *	1992-05-19	1992-05-19	Kabi Pharmacia Ab	Use of igf-1
GB9217696D0 (en) *	1992-08-20	1992-09-30	Agricultural & Food Res	Use of specific binding molecules
US5407913A (en) *	1992-12-03	1995-04-18	Celtrix Pharmaceuticals, Inc.	Method and composition for systemic treatment of tissue injury
WO1994016722A1 (fr) *	1993-01-25	1994-08-04	The Beth Israel Hospital Association	Procede de modification, de diagnostic et de depistage de caracteristiques de barriere cellulaire sensibles a l'igf-i
US5563046A (en) *	1993-08-02	1996-10-08	Celtrix Pharmaceuticals, Inc.	Fusion polypeptides and proteins
CA2168790A1 (fr) *	1993-08-03	1995-02-09	Christopher A. Maack	Methode pour traiter les troubles de la reproduction
EP0726911B1 (fr) *	1993-09-20	2002-10-30	Celtrix Pharmaceuticals, Inc.	Traitement de troubles hematologiques a l'aide d'un complexe des igf-1/igfbp-3
JPH09509141A (ja) *	1993-11-15	1997-09-16	セルトリックスファーマシューティカルズ，インコーポレイテッド	Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
JPH09509140A (ja) *	1993-11-15	1997-09-16	セルトリックスファーマシューティカルズ，インコーポレイテッド	神経学的障害の治療方法
EP0800530A4 (fr) *	1994-07-20	1998-12-02	Celtrix Pharma	Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
US5741776A (en) *	1995-05-22	1998-04-21	Genentech, Inc.	Method of administration of IGF-I
US6436897B2 (en) *	1998-06-01	2002-08-20	Celtrix Pharmaceuticals, Inc.	Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes

1999
- 1999-06-04 US US09/326,189 patent/US6040292A/en not_active Expired - Lifetime
2000
- 2000-05-23 JP JP2001501244A patent/JP2003501397A/ja active Pending
- 2000-05-23 WO PCT/US2000/014163 patent/WO2000074710A2/fr not_active Ceased
- 2000-05-23 MX MXPA01013384A patent/MXPA01013384A/es active IP Right Grant
- 2000-05-23 CN CNB008112649A patent/CN1235637C/zh not_active Expired - Fee Related
- 2000-05-23 AU AU50411/00A patent/AU780400B2/en not_active Ceased
- 2000-05-23 KR KR1020017015628A patent/KR100694737B1/ko not_active Expired - Fee Related
- 2000-05-23 AT AT00932729T patent/ATE271880T1/de active
- 2000-05-23 EP EP00932729A patent/EP1183042B1/fr not_active Expired - Lifetime
- 2000-05-23 IL IL14686800A patent/IL146868A0/xx not_active IP Right Cessation
- 2000-05-23 CA CA002373281A patent/CA2373281C/fr not_active Expired - Fee Related
- 2000-05-23 ES ES00932729T patent/ES2222208T3/es not_active Expired - Lifetime
- 2000-05-23 DE DE60012517T patent/DE60012517T2/de not_active Expired - Lifetime
2001
- 2001-12-04 NO NO20015932A patent/NO324117B1/no not_active IP Right Cessation
- 2001-12-19 ZA ZA200110408A patent/ZA200110408B/xx unknown

Also Published As

Publication number	Publication date
EP1183042B1 (fr)	2004-07-28
CN1387440A (zh)	2002-12-25
NO20015932L (no)	2002-01-31
US6040292A (en)	2000-03-21
ATE271880T1 (de)	2004-08-15
WO2000074710A3 (fr)	2001-06-28
HK1044895A1 (en)	2002-11-08
CN1235637C (zh)	2006-01-11
AU5041100A (en)	2000-12-28
KR100694737B1 (ko)	2007-03-14
KR20020020723A (ko)	2002-03-15
CA2373281C (fr)	2010-01-12
DE60012517D1 (de)	2004-09-02
ES2222208T3 (es)	2005-02-01
ZA200110408B (en)	2003-03-19
WO2000074710A2 (fr)	2000-12-14
AU780400B2 (en)	2005-03-17
JP2003501397A (ja)	2003-01-14
MXPA01013384A (es)	2003-09-04
DE60012517T2 (de)	2005-08-04
IL146868A0 (en)	2002-08-14
CA2373281A1 (fr)	2000-12-14
NO20015932D0 (no)	2001-12-04
EP1183042A2 (fr)	2002-03-06

Legal Events

Date	Code	Title	Description
2011-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
American Diabetes Association	2020	9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020
American Diabetes Association Professional Practice Committee et al.	2022	9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2022
EP1183042B1 (fr)	2004-07-28	Methodes de traitement du diabete
CA1336815C (fr)	1995-08-29	Methode de prevention des effets secondaires
Reinhart et al.	2002	Insulin glargine: A new long-acting insulin product
Hermansen et al.	2016	Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience
Brunton et al.	2006	Overcoming psychological barriers to insulin use in type 2 diabetes
Berger	1987	Human insulin: much ado about hypoglycaemia (un) awareness
Rosenstock	2001	Insulin therapy: optimizing control in type 1 and type 2 diabetes
Sonnenberg et al.	1982	Human and porcine regular insulins are equally effective in subcutaneous replacement therapy: results of a double-blind crossover study in type I diabetic patients with continuous subcutaneous insulin infusion
Rodger	1991	Insulin-dependent (type I) diabetes mellitus
NZ534557A (en)	2007-10-26	Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
US5948757A (en)	1999-09-07	High dose IGF-1 therapy
Escobar et al.	2003	Management of the child with diabetes
HK1044895B (en)	2005-04-01	Methods for treating diabetes
Zinman et al.	1996	Insulin lispro in CSII: results of a double-blind crossover study.
Rosenbloom	2001	IGF‐I treatment of diabetes
Agent et al.	2021	LIPRELOG™
Hughes and et al.	2022	Short‐acting Insulin Analogues
Galli-Tsinopoulou	2011	Insulin therapy in children and adolescents with diabetes
Magee et al.	2007	Insulin therapy in adults with type 1 diabetes mellitus
Maffeo	2006	Medication Management
Jones et al.	2006	Insulin detemir: a long-acting insulin product [corrected][published erratum appears in AM J HEALTH SYST PHARM AJHP 2007 Feb 15; 64 (4): 346].
Torlone	1998	Recombinant human insulin analogues: recommendations for optimal use
Springer	2004	Basal Insulin in Combination With Oral Hypoglycemic Agents in the Management of Type 2 Diabetes